Thanks for the additional insights. My initial point for posting the finding was to form a basis for approval of LL in the UK based on predicted cd12 results. From what we've gleaned from tocilizumab and sarilumab approval, I think LL can easily beat 25% reduction in mortality, is a monotherapy, and extremely safe.